Secretin in Ex-situ Liver Perfusion

Enrolling by invitation · Phase 1/Phase 2

Conditions studied: Liver Transplantation

In brief

The main objective is to assess whether the use of human synthetic secretin in a clinical (COR-)NMP procedure can restore physiological HCO3- content of the bile during ex-situ NMP.

Key facts

Study ID

NCT07651748

Run by

Erasmus Medical Center

People needed

20

Starts

2025-04-26

Expected to finish

2026-10-01

Last updated by the study team

2026-06-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients (>18 years old)
• Donor livers that required resuscitation and viability assessment through the previously published sequential hypo- and normothermic liver machine perfusion (DHOPE-COR-NMP) protocol based on a blood-based perfusate.

You may not qualify if…

• Multiorgan transplantation
• Split liver transplant
• Living donor liver transplantation
• Organ donation after Euthanasia
• Previous donor organ perfusion (e.g. Normothermic Regional Perfusion)

Where it is running

• Erasmus Medical Center — Rotterdam, South Holland, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.